Search
Tenoxicam
go.drugbank.com/drugs/DB00469ApprovedInvestigationalTenoxicam, an antiinflammatory agent with analgesic and antipyretic properties, is used to treat osteoarthritis and control acute pain.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 SubstratesVericiguat
go.drugbank.com/drugs/DB15456ApprovedInvestigational[L31178] Vericiguat was approved by the FDA in January 2021 - developed by Merck under the brand name Verquvo - for use in certain patients with systolic heart failure. … to its structure have dramatically decreased its susceptibility to oxidative metabolism,[A227458] resulting in a relatively long half-life and allowing for once-daily dosing.
Categories: P-glycoprotein substratesGefapixant
go.drugbank.com/drugs/DB15097Approvedthe cough can be determined. … It received approval in both Japan and Switzerland in 2022 for the treatment of adult patients with RCC and UCC, and received subsequent approval in the EU in September 2023 for the same indications.
Categories: P-glycoprotein substratesClobazam
go.drugbank.com/drugs/DB00349ApprovedIllicitInvestigational[A256958] In 2005, clobazam also received approval from Health Canada as an add-on therapy for generalized tonic-clonic, myoclonic, and focal impaired awareness seizures.[A256978] … [A521,A522] In October 21, 2011, the FDA approved clobazam as an adjunctive treatment for seizures associated with Lennox-Gastaut syndrome in adults and children aged two years and older.
Categories: GABA-A Receptor Agonists, P-glycoprotein substratesDuvelisib
go.drugbank.com/drugs/DB11952ApprovedInvestigationalDuvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma can
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesProtriptyline
go.drugbank.com/drugs/DB00344ApprovedSee toxicity section below for a complete listing of side effects. Protriptyline may be used for the treatment of depression. … They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, protriptyline does not affect mood or arousal, but may cause sedation.
Categories: P-glycoprotein inhibitors, Antidepressive Agents Indicated for DepressionRelugolix
go.drugbank.com/drugs/DB11853ApprovedInvestigational[A225926] In May 2021, the FDA approved the combination product made up of relugolix, [estradiol], and [norethindrone] under the market name Myfembree for the first once-daily treatment for the management … Orgovyx, for the treatment of advanced prostate cancer.
Categories: Gonadotropin Releasing Hormone Receptor Antagonists, P-glycoprotein inhibitorsMaraviroc
go.drugbank.com/drugs/DB04835ApprovedInvestigationalIt was approved for use by the FDA in August, 2007. … Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseSarecycline
go.drugbank.com/drugs/DB12035ApprovedInvestigationalSarecycline is a semi-synthetic derivative of tetracycline that was initially discovered by Paratek Pharmaceuticals from Boston, MA but then licensed to Warner Chilcott of Rockaway, NJ in July of 2007 … s Seysara (sarecylcine) as a new first in class narrow spectrum tetracycline derived oral antibiotic for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients
Categories: P-glycoprotein inhibitors, Antibacterials for Systemic UseTolbutamide
go.drugbank.com/drugs/DB01124ApprovedTolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). … Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk.
Categories: Tests for Diabetes, Cytochrome P-450 SubstratesSynonyms: 1-Butyl-3-(p-tolylsulfonyl)urea, 1-p-Toluenesulfonyl-3-butylurea